MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the lead plaintiff deadline on December 15, 2025 for a class action lawsuit [1] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the differences between Nanobodies and monoclonal antibodies, specifically about SLK and BIMZELX [5] - Key misleading claims include that SLK and BIMZELX share the same molecular targets, that SLK's Nanobody structure would not provide superior clinical benefits, and that its supposed tissue penetration would not lead to clinical efficacy [5] Legal Process - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]